Compare MLP & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLP | IRWD |
|---|---|---|
| Founded | 1909 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.2M | 251.8M |
| IPO Year | 1972 | 2010 |
| Metric | MLP | IRWD |
|---|---|---|
| Price | $17.27 | $3.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.34 |
| AVG Volume (30 Days) | 45.7K | ★ 2.3M |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | $18,344,000.00 | ★ $338,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.01 |
| P/E Ratio | ★ N/A | $20.22 |
| Revenue Growth | ★ 73.55 | N/A |
| 52 Week Low | $13.84 | $0.53 |
| 52 Week High | $23.41 | $5.13 |
| Indicator | MLP | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 64.06 | 61.99 |
| Support Level | $16.05 | $3.50 |
| Resistance Level | $17.56 | $3.80 |
| Average True Range (ATR) | 0.59 | 0.33 |
| MACD | 0.20 | -0.05 |
| Stochastic Oscillator | 86.32 | 58.96 |
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.